Global Liquid Biopsy Market Size By Circulating Biomarker(Circulating Tumour Cells (CTCs), Circulating Tumour DNA (CTDNA), Cell-Free DNA (cfDNA) & Others), By End User (Reference Laboratories, Hospitals and Physician Laboratories, & Other), By Application (Cancer & Non-Cancer Applications), By Produ

Liquid Biopsy Market Size And Forecast

Liquid Biopsy Market size was valued at USD 4.17 Billion in 2022 and is projected to reach USD 16.09 Billion by 2030, growing at a CAGR of 18.39% from 2024 to 2030.

The next-generation sequencing for advanced cancer patients using liquid biopsies, an increase in the number of cancer patients, and a rise in patient demand for minimally invasive therapies are all contributing to the growth of the liquid biopsy market. Unfortunately, the lack of knowledge of liquid biopsy in developing nations limits business expansion. The use of liquid biopsy testing to treat uncommon cancers and the rise in healthcare spending in developing nations like China and India, however, are likely to create several potentials for market expansion. The Global Liquid Biopsy Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Liquid Biopsy Market Definition

A lab inspection of a sample of Urine, Blood, or another bodily fluid to search for cancer cells from a tumor or tiny fragments of RNA, DNA, or other chemicals released by tumor cells into the subject’s bodily fluids. To have a better understanding of the type of molecular or genetic alterations which occur in a tumor different varieties of samples can be collected over time with a liquid biopsy, which may help medical professionals. Cancer can be detected at an early stage by the use of liquid biopsy. Moreover, it could be used to determine the effectiveness of the treatment, how well it is functioning, or whether cancer has returned.

Liquid biopsy is the specimen and research of non-solid biological tissue, typically blood and it is also known as a fluid phase biopsy or fluid biopsy. A Standard biopsy is the type of method, which has the advantage of being largely non-invasive and is mostly employed as a monitoring and diagnostic tool for disorders like cancer. Liquid biopsies can also be performed to confirm the efficacy of a cancer therapy drug by gathering multiple samples over a few weeks. Patients may use the equipment to monitor relapse after treatment.

The molecular assessment of nucleic acids, subcellular components, especially exosomes, and, in the case of cancer, , in physiological fluids is known as “liquid biopsy”. In the past 10 years, liquid biopsy has been the focus of significant studies to offer a less invasive and more precise form of personalized therapy. The molecular evaluation of these circulating indicators can supplement or even take the place of tissue biopsies. This discovery led to the implementation of liquid biopsy in clinical practice, particularly in , prenatal screening, and transplantation. Here, we look at the biology, methodology, and therapeutic applications of the important liquid biopsy indicators.

Global Liquid Biopsy Market Overview

Liquid biopsy is an easy, quick, non-invasive, and repeatable sampling technique that can reflect changes in tumor profiles and offer a solid foundation for a customized treatment and cancer early detection. The focus in recent years has also been on early cancer detection, tracking the development of tumors, evaluating therapy response and clinical prognosis, and identifying recurrent and refractory cancers. Furthermore, due to technological advancements in both practicality and turnaround time, liquid biopsy has recently attracted a lot of attention as a non-invasive substitute procedure for tissue biopsy in patients with cancer.

Over the past ten years, Global health organizations’ campaigns for raising awareness of cancer Governments from Different nations and international health organizations have launched several campaigns to raise cancer awareness. For instance, the WHO’s National Cancer Control Program is a public health mission to drop the number of cancer-related deaths and improve the quality of life for cancer patients. Similarly, the US Centers for Diseases and Prevention (CDC) launched the National Cervical and Breast Early Detection Program (NBCCEDP) in 1991, which annually offers breast cancer screening and diagnosis to low-income and uninsured patients in the US. In 2020, this program provided and screening services to 260,143 women. Additionally, 116,562 women received services from this project in the same year for and screening.

The quantities of CTDNA of any particular cancer mutation may be very low in the plasma of a cancer patient, especially after treatment or surgery, making the technical task of detecting cDNA in liquid biopsies difficult. Some tumor forms, such as sarcomas, are poor cDNA shedders, which presents a challenge for cDNA profiling and limits the applicability of cDNA to all cancers. Low amounts of CTDNA are hypothesized to be caused by the blood-brain barrier, tumor vascularity, or location (such as bone lesions).

For leading businesses functioning in the liquid biopsy market, emerging economies like India, China, South Korea, Brazil, Turkey, Russia, and South Africa are anticipated to present substantial growth possibilities. This can be linked to the greater cancer prevalence, sizable patient population, expanding medical tourism, better healthcare infrastructure, and rising disposable income in these nations. The Asia Pacific area has become a flexible and business-friendly hub because of fewer onerous rules and data requirements than the previously mentioned criteria.

The adoption of liquid biopsy testing is hampered by low reimbursement (non-coverage for panel-based tests). The NCD guidelines helped Foundation One’s genomic profiling assay get approved, but they might work against other firms creating NGS-panel diagnostics in the LDT scenario. When a business requests a local coverage decision (LCD), Medicare administrative contractors (MACs) must decide whether to provide coverage if multigene NGS tests have not received FDA approval or reimbursement coverage. However, we find that the majority of MACs favor the NCD to make the decision, which is likely to be detrimental for liquid biopsy firms.

Global Liquid Biopsy MarketSegmentation Analysis

The Global Liquid Biopsy Market is segmented on the basis of Product and Service, Application, Clinical Application, Circulating Biomarker, End-User, and Geography.

Liquid Biopsy Market by Circulating Biomarker

• Circulating Tumor Cells (CTCs)
• Circulating Tumor DNA (ctDNA)
• Cell-Free DNA (cfDNA)
• Extracellular Vesicles (EVs)
• Other Circulating Biomarkers

Based on Circulating Biomarker, the global Liquid Biopsy Market has been segmented into Circulating Tumour Cells (CTCs), Circulating Tumour DNA (CTDNA), Cell-Free DNA (cfDNA), Extracellular Vesicles (EVS), and others. Circulating Tumour Cells accounted for the largest market share in 2020, during the forecast period. Circulating Tumour DNA (ctDNA) was the second-largest market in 2020. Circulating Tumour cells (CTCs) are considered to have an encouraging perspective as a liquid biopsy that can simplify early detection, prognosis, therapeutic target selection, and monitoring therapeutic response. Circulating Tumour DNA (ctDNA) is originates in the bloodstream and can be described as DNA that comes from cancerous cells and tumors.

Liquid Biopsy Market by End User

• Reference Laboratories
• Hospitals and Physician Laboratories
• Academic and Research Centers
• Other End Users

Based on End-User, the global Liquid Biopsy Market has been segmented into Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centres, and Other. Reference Laboratories accounted for the largest market in 2020, during the forecast period. Hospitals and Physician Laboratories was the second-largest market in 2020 However, Academic and Research Centres is projected to grow at the highest.

Liquid Biopsy Market by Application

• Cancer Applications
  •  Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Melanoma Cancer
  • Other Cancers
• Non-Cancer Application

To Get Summarized Market Report By Application-

Based on Application, the global Liquid Biopsy Market has been segmented into Cancer Applications and Non-Cancer Applications. Cancer Applications accounted for the largest market in 2020 during the forecast period. Non-Cancer Applications was the second-largest market in 2020. The advent of the liquid biopsy leads to the emergence of a better understanding of the molecular diagnostic of the circulating Tumour DNA. The high adoption rate of liquid biopsy in cancer application is owing to its potential of non-invasive detection of the targeted genomic alteration in correspondence to targeted therapy. The non-cancerous tumors are not life-threatening. In addition, the non-cancerous application of the liquid biopsy also includes the diagnosis of prenatal, heart attack, and atherosclerosis.

Liquid Biopsy Market by Product and Services

• Assays Kits
• Instruments
• Services

Based on Product and Service, the Global Liquid Biopsy Market has been segmented into Assay Kits, Instruments, and Services. Instruments & Platforms accounted for the largest market in 2020 during the forecast period. Kits & Reagents was the second-largest market in 2020. A kit generally consists of all the materials/apparatus required to carry out any experiment. Kits are a complete package of all the requirements needed to carry out a liquid biopsy. The advance in liquid biopsy allows an alternative and attractive non-invasive procedure to obtain from cancers for diagnosis. The services are defines as analytical services for a wide range of liquid biopsy applications.

Liquid Biopsy Market by Clinical Application

• Early Cancer Screening
• Therapy Selection
• Treatment Monitoring
• Recurrence Monitoring

Based on Clinical Application, the global Liquid Biopsy Market has been segmented into Early Cancer Screening, Therapy Selection, Treatment Monitoring, and Recurrence Monitoring. Early Cancer Screening accounted for the largest in 2020, during the forecast period. Therapy Selection was the second-largest market in 2020. However, Treatment Monitoring is projected to grow.The therapy selection is the method that is been applied to evaluate the relief or even the cure of the diseases. The monitoring of the recurrence of cancer is one of the very essential parts involving routine physical exams and medical imaging. The early cancer screening process starts with the suspicious lesions found by CT scan and their property identification is confirmed by the liquid biopsy.

Liquid Biopsy Market by Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

To Get Summarized Market Report By Geography- 

On the basis of regional analysis, the Global Liquid Biopsy Market is classified into North America, Europe, Asia Pacific, and Rest of the world. Asia-Pacific accounted for the largest market share and North America was the second-largest in 2021. Asia Pacific region is considered to be the biggest production center of Liquid Biopsy as it has emerged as a major producer and supplier of Liquid Biopsy to the entire world. The manufacturing operations in the Asia-Pacific region have expanded owing to several acquisitions and the opening of new sites in the region.

Key Players

The Liquid Biopsy Market is highly fragmented with the presence of a large number of players globally. Some of the major companies include Roche Diagnostics, Biocept, Inc., Thermo Fisher Scientific Inc. Qiagen N.V., Bio-Rad Laboratories, Inc., Menarini-Silicon Biosystems, Illumina, Inc., MDXhealth SA, Genomic Health, Inc., and Guardant Health Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• Roche launched it’s CE Mark-approved Cobas EGFR Mutation Test v2 in Europe.
• Biocept Entered into Agreement with Alliance Global FZ to Market. This agreement resulted in the Distribution of Liquid Biopsy Testing in the Middle East, Southeast Asia, and Africa Region.
• Thermo Fisher Scientific Expanded Oncomine Immuno-Oncology Assay Portfolio. This assay enabled site-specific interrogation for T-cell receptor applications.
• In December 2020, Guardant Health launches a liquid biopsy test for cancer patients, called Guardant Reveal, which can detect residual disease after treatment.
• In August 2021, Freenome, a company specializing in liquid biopsy tests for early cancer detection, goes public with a valuation of $5.5 billion.

Report Scope

Top Trending Reports

Research Methodology of Market Research